Amgen Net Income From Continuing Ops from 2010 to 2026

AMGN Stock  USD 366.20  0.38  0.10%   
Amgen Net Income From Continuing Ops yearly trend continues to be very stable with very little volatility. Net Income From Continuing Ops is likely to grow to about 6.3 B this year. During the period from 2010 to 2026, Amgen Net Income From Continuing Ops quarterly data regression pattern had sample variance of 3103272.1 T and median of  5,893,000,000. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2000-03-31
Previous Quarter
1.4 B
Current Value
3.2 B
Quarterly Volatility
B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 B, Interest Expense of 2.9 B or Selling General Administrative of 2.7 B, as well as many indicators such as Price To Sales Ratio of 8.8, Dividend Yield of 0.0194 or PTB Ratio of 21.36. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Build AI portfolio with Amgen Stock
Check out the analysis of Amgen Correlation against competitors.
Evaluating Amgen's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Amgen Inc's fundamental strength.

Latest Amgen's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Amgen Inc over the last few years. It is Amgen's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amgen's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Amgen Net Income From Continuing Ops Regression Statistics

Arithmetic Mean5,771,977,941
Geometric Mean5,466,047,886
Coefficient Of Variation30.52
Mean Deviation1,474,273,356
Median5,893,000,000
Standard Deviation1,761,610,662
Sample Variance3103272.1T
Range6.4B
R-Value0.27
Mean Square Error3061111.1T
R-Squared0.08
Significance0.29
Slope95,687,500
Total Sum of Squares49652354T

Amgen Net Income From Continuing Ops History

20266.3 B
20254.7 B
20244.1 B
20237.6 B
20226.6 B
20215.9 B
20207.3 B

About Amgen Financial Statements

Amgen investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Amgen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income From Continuing Ops4.7 B6.3 B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving against Amgen Stock

  0.63LYRA Lyra TherapeuticsPairCorr
  0.59ABP Abpro HoldingsPairCorr
  0.57EDIT Editas Medicine Earnings Call This WeekPairCorr
  0.56QSI QuantumSiPairCorr
  0.49KURA Kura OncologyPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Will Biotechnology sector continue expanding? Could Amgen diversify its offerings? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amgen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.116
Dividend Share
9.52
Earnings Share
14.22
Revenue Per Share
68.31
Quarterly Revenue Growth
0.086
Investors evaluate Amgen Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Amgen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Amgen's market price to deviate significantly from intrinsic value.
Understanding that Amgen's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amgen represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Amgen's market price signifies the transaction level at which participants voluntarily complete trades.